FDA notifications. BMS issues letter about omeprazole.
D019540:Area Under Curve; D000069446:Atazanavir Sulfate; D004345:Drug Industry; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D009842:Oligopeptides / Q000493:pharmacokinetics / Q000627:therapeutic use; D009853:Omeprazole / Q000493:pharmacokinetics / Q000627:therapeutic use; D011725:Pyridines / Q000493:pharmacokinetics / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D019438:Ritonavir / Q000493:pharmacokinetics / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate; D009853:Omeprazole; D019438:Ritonavir